Combination of T cell-redirecting bispecific antibody ERY974 and ...
2022年9月7日 · ERY974 is a humanized IgG4 bispecific T cell-redirecting antibody that recognizes glypican-3 and CD3. Here we examine the combination effect of ERY974 and chemotherapy (paclitaxel, cisplatin,...
肝癌细胞治疗领域的宠儿GPC3 - 知乎 - 知乎专栏
在gc33的基础上，中外制药开发出一款双特异性抗体ery974。 ERY974抗体可以识别GPC3和CD3双抗原，在T细胞和肿瘤细胞之间构成了免疫突触，介导T细胞杀伤GPC3过表达的肿瘤细胞。
An anti–glypican 3/CD3 bispecific T cell–redirecting ... - Science
2017年10月4日 · We developed ERY974, a whole humanized immunoglobulin G–structured TRAB harboring a common light chain, which bispecifically binds to GPC3 and CD3. Using a mouse model with reconstituted human immune cells, we revealed that ERY974 is highly effective in killing various types of tumors that have GPC3 expression comparable to that in clinical ...
Abstract CT111: Results of a phase 1 dose escalation study of ERY974 …
2021年7月1日 · ERY974 demonstrates T cell-dependent cellular cytotoxicity in vitro and transient cytokine elevations in preclinical toxicology studies (Ishiguro et al. 2017). The primary objective of this dose escalation (DE) study was to determine ERY974's maximum tolerated dose in patients with locally advanced or metastatic solid tumors expressing GPC3.
肝细胞癌标记物GPC3 - mabnus.cn
2024年9月25日 · ERY-974是由Chugai Pharmaceutical在单抗GPC3的基础上开发的一种靶向GPC3和CD3的双特异性抗体。ERY974抗体可以识别GPC3和CD3双抗原，在T细胞和肿瘤细胞之间构成了免疫突触，介导T细胞杀伤GPC3过表达的肿瘤细胞。目前处于临床l期阶段用于治疗转移性肝癌。2022年9月Sano, Y等 ...
ERY-974 (ERY-974) - 药物靶点：CD3 x GPC3_专利_临床_研发
To understand human T-cell activation and chromatin states after priming treatment with CD3 bispecific construct targeting CD3ɛ and glypican 3 (ERY974), we examined cytokine levels, cytokine mRNA expression, CD3ɛ expression, CD3-mediated signal transduction, T cell activation markers, cytotoxicity against target cells, and chromatin states in ...
聚焦药靶：肝细胞癌治疗的新曙光，GPC3的最新研究进展
此外，中外制药在gc33的基础上还开发了一款靶向cd3/gpc3的双特异性抗体，即ery974。 ERY974抗体带有2个不同的可变区，其中一个识别肿瘤抗原GPC3，另一个用于结合表达CD3抗原的T细胞。
Determination of starting dose of the T cell-redirecting ... - Nature
2022年7月19日 · Currently, ERY974, a humanized IgG4 bispecific T cell-redirecting antibody recognizing glypican-3 and CD3, is in phase I clinical trials.
tumour through ERY974-induced IFN γ and TNFα in T cells. We show that ERY974 with chemotherapy synergistically and reciprocally increases anti-tumour efficacy, eradicating non-inflamed tumours.
CNS前沿文献追踪 - 肿瘤免疫新“玩法” - 双特异性抗体ERY974
2017年10月16日 · 提到肿瘤免疫疗法人们最先想起的往往是CART或免疫检查点抑制剂，这次分享一个新的肿瘤免疫治疗策略-双特异性抗体ERY974（已进入临床一期试验），如上图：抗体带有两个不同的可变区，其中一个识别结合肿瘤抗原glypican 3，另一个用于结合T细胞，双特异性抗体 ...